

# Anticoagulating patients with high-risk acquired thrombophilias

Leslie Skeith

Division of Hematology and Hematological Malignancies, Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Canada; and Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada

Antiphospholipid syndrome (APS), heparin-induced thrombocytopenia, and paroxysmal nocturnal hemoglobinuria are 3 acquired thrombophilias that carry a high risk of venous and arterial thromboembolism. Management of these conditions has largely included anticoagulation with a vitamin K antagonist after an initial period of a parenteral anticoagulant, for as long as the thrombotic risk is still present. The available evidence for the use of direct oral anticoagulants (DOACs) is limited and primarily consists of case series and cohort studies, which are summarized in this chapter. Randomized trials evaluating DOACs in patients with APS are reviewed. Further research is needed prior to widely adopting DOACs for use in these high-risk acquired thrombophilias; however, there may be selected low-risk subgroups where DOAC use is possible after careful consideration and patient discussion.

### Learning Objectives

- Describe the thrombotic risk associated with antiphospholipid syndrome (APS), heparin-induced thrombocytopenia (HIT), and paroxysmal nocturnal hemoglobinuria (PNH)
- Apply the available evidence about direct oral anticoagulant use to make anticoagulant decisions for patients with APS, HIT, and PNH

### Introduction

Antiphospholipid syndrome (APS), heparin-induced thrombocytopenia (HIT), and paroxysmal nocturnal hemoglobinuria (PNH) are 3 acquired conditions with potent prothrombotic states that affect both the venous and arterial circulation and require special anticoagulant considerations. With the widespread use of direct oral anticoagulants (DOACs) for the treatment and secondary prevention of venous thromboembolism (VTE) in the general population, it begs the question: is there a role for DOACs in patients with APS, HIT, or PNH?

The pathogenesis of thromboembolic disease in APS, HIT, and PNH differs from that of the general VTE population and includes cellularand/or complement-mediated mechanisms.<sup>1-3</sup> There is a higher incidence of arterial thromboembolism (ATE) as well as recurrent VTE while on anticoagulation when compared with other thrombotic conditions. DOACs are convenient and may provide more stable anticoagulation compared with vitamin K antagonists (VKAs) such as warfarin, but there are possible disadvantages to their use because of their pharmacokinetic profiles. Unlike warfarin, DOACs have only 1 molecular target so could be less effective in potent thrombophilic states. Anticoagulant doses needed to prevent arterial thrombosis are higher, so DOACs may not be adequate.<sup>4</sup> Lastly, DOACs' short halflives may theoretically lead to additional "breakthrough" thrombosis and anticoagulation failures. Evidence is needed before we can widely adopt the use of DOACs in these high-risk populations.

This chapter provides a basic overview of APS, HIT, and PNH and reviews the thrombotic risk in each condition. The emphasis will be on anticoagulant management, with a focus on the available evidence and current role of the DOACs.

## Possibility of DOAC use: extrapolation from the cancer-associated VTE literature

Using DOACs in other prothrombotic states is theoretically possible based on evidence from the cancer-associated VTE literature. As a highly prothrombotic state, cancer and its treatment is associated with recurrent VTE despite therapeutic anticoagulation.<sup>5,6</sup> In the recent Hokusai randomized trial, edoxaban was noninferior to lowmolecular-weight heparin (LMWH) for its composite end point (recurrent VTE or major bleeding) in patients with active cancer, with fewer recurrent VTE events in the edoxaban arm.<sup>7</sup> These data are supported by other studies showing similar outcomes in DOACtreated cancer patients.<sup>8,9</sup> However, there was also an increased bleeding risk among Hokusai patients who were randomized to DOACs, particularly among certain subgroups of cancer patients, highlighting the importance of disease-specific considerations and differing underlying pathophysiology.<sup>7</sup> Thus, while the use of DOACS in other acquired thrombophilias is theoretically possible, we must look to the available disease-specific evidence to determine the optimal use of DOACs in our patients.

Conflict-of-interest disclosure: L.S. has received research funding and from CSL Behring and honoraria from Leo Pharma. Off-label drug use: None disclosed.

This article was selected by the Blood and Hematology 2018 American Society of Hematology Education Program editors for concurrent submission to Blood and Hematology 2018. It is reprinted from Blood 2018, Volume 132.

# Downloaded from http://ashpublications.net/hematology/article-pdf/2018/1/439/1252329/hem01861.pdf by guest on 17 May 2024

### APS

### APS and the risk of thrombosis

APS is a systemic autoimmune disorder characterized by thrombotic and/or obstetrical complications and persistently positive antiphospholipid antibodies (APLA). Autoantibodies to phospholipidbinding proteins are thought to be pathogenic through a variety of mechanisms, including interacting with the coagulation and fibrinolytic systems, monocyte and neutrophil activation, endothelial cell activation, and complement-mediated processes.<sup>1,10</sup>

The consensus-based revised Sapporo/Sydney classification criteria were initially developed for research purposes and can aid in the diagnosis of APS.<sup>1</sup> The revised Sapporo/Sydney classification criteria require at least 1 laboratory criterion and 1 clinical criterion to define APS (Table 1). This includes (but is not limited to) VTE (pulmonary embolism or deep vein thrombosis including at unusual sites) or ATE such as stroke or myocardial infarction.<sup>11</sup> Catastrophic APS is an aggressive variant of APS with multi–organ system involvement that includes small vessel thrombosis and can develop rapidly.<sup>12</sup>

Lupus anticoagulant (LAC) has been consistently associated with a first episode of VTE and ATE, whereas studies report a variable thrombotic risk with anticardiolipin (aCL) according to the study design and antibody titer cutoffs used.<sup>13,14</sup> Anti- $\beta$ 2 glycoprotein 1 (a $\beta$ 2GP1) antibodies are likely associated with a modest risk of thrombosis, but the risk has been variably reported.<sup>15,16</sup> While not widely available or part of the revised Sapporo/Sydney classification criteria, immunoglobulin G (IgG) a $\beta$ 2GP1 antibodies specific to domain 1 have been associated with an increased risk of thrombosis.<sup>17,18</sup>

### Table 1. Revised Sapporo/Sydney classification criteria for APS

### APS is present if at least 1 clinical criterion and 1 laboratory criterion are met

### Clinical criteria

- 1. Vascular thrombosis
  - One or more objectively confirmed arterial, venous or small vessel thrombosis in any tissue or organ. For histopathologic confirmation, thrombosis should be present without significant vessel wall inflammation.
- 2. Pregnancy morbidity
  - a. One or more unexplained deaths of a morphologically normal fetus at or beyond the 10th week of gestation or
  - b. ≥1 premature birth of a morphologically normal neonate before the 34th week of gestation because of (1) eclampsia or severe preeclampsia defined according to standard definitions or (2) recognized features of placental insufficiency or
  - c. ≥3 unexplained consecutive spontaneous abortions before the 10th week of gestation, with maternal anatomic or hormonal abnormalities and paternal and maternal chromosomal causes excluded

### Laboratory criteria

- Lupus anticoagulant present in plasma on ≥2 occasions at least 12 weeks apart, detected according to the guidelines of the International Society on Thrombosis and Haemostasis
- 2. Anticardiolipin antibody of IgG and/or IgM isotype in serum or plasma, present in medium or high titer (>40 GPL or MPL, or >99th percentile) on ≥2 occasions, at least 12 weeks apart, measured by standardized ELISA
- 3. Anti-β2 glycoprotein 1 antibody of IgG and/or IgM isotype in serum or plasma (in titer >99th percentile) present on ≥2 occasions, at least 12 weeks apart, measured by standardized ELISA

Adapted from Miyakis et al<sup>11</sup> with permission.

ELISA, enzyme-linked immunosorbent assay.

The risk of initial thrombosis is likely <1% among carriers with incidental APLA.<sup>19-21</sup> The risk of initial thrombosis is higher when multiple APLA test results are positive and may be as high as 5% per year and 37% after 10 years for individuals with triple-positive results (positive LAC, aCL, and aβ2GP1 antibodies).<sup>22,23</sup>

Because of uncertainty around the risk of recurrent VTE in APS,<sup>24-28</sup> Garcia et al conducted a meta-analysis in patients with prior VTE and positive APLA (LAC or aCL) compared with patients with negative APLA.<sup>29</sup> Among 3114 patients from 8 studies, the relative risk of VTE recurrence was 1.41 (95% confidence interval [CI], 0.99-2.36) among patients with positive APLA compared with negative APLA patients, and 1.94 (95% CI, 0.84-4.46) when only unprovoked VTE events were included.<sup>29</sup> This reported VTE risk reflects a carefully selected subgroup of patients from published studies. However, definitive conclusions cannot be made because laboratory testing was only completed at a single time point and differing antibody level cutoffs were used between studies. Recently, Kearon et al completed a prospective cohort study where the authors systematically tested for LAC, aCL, and aß2GP1 over multiple time points in 290 patients with unprovoked VTE who had stopped anticoagulation in response to negative D-dimer testing after receiving 3 to 7 months of anticoagulation.<sup>30</sup> Among a subgroup of patients who had persistently positive APLA on 2 occasions (consistent with the revised Sapporo/Sydney classification criteria), the rate of recurrent VTE was 13.0% per person-year, which was higher than the negative APLA group (hazard ratio, 2.7; 95% CI, 1.1-6.7; P = .03) and did not change with sex or estrogen status. The authors also found that different types of positive APLAs in the same patient on the same or different occasions had a higher recurrence risk of 21.1% per personyear, which is in keeping with previous studies.<sup>30,31</sup> This study provides additional evidence in favor of long-term anticoagulation as well as laboratory screening in patients who present with unprovoked VTE, especially if they are otherwise deemed to be at low risk of VTE recurrence and are planning to stop anticoagulation.<sup>32-34</sup>

### Anticoagulant management in APS

In 2018, the gold-standard treatment of an APS patient with VTE is still a VKA with a target international normalized ratio (INR) of 2 to  $3^{35,36}$  after an initial overlap with LMWH or unfractionated heparin (UFH). The available DOAC data in the APS population are limited, with recent randomized trial data showing an increased risk of thrombosis among high-risk APS patients treated with DOACs.<sup>37</sup>

Patients with APS were not excluded from the original DOAC VTE treatment trials; however, limited information is available for this patient subgroup. A small post hoc analysis of possible APS patients who received dabigatran vs VKA showed no difference in VTE recurrence rates.<sup>38</sup>

Several case series and cohort studies report recurrent thrombosis risks ranging from 0% to 75%, with lower recurrent thrombotic risks reported among larger prospective studies (Table 2).<sup>39,40</sup> In my review of all published studies that included  $\geq$ 5 patients, the pooled proportion for recurrent venous, arterial, and microthrombosis among 458 DOAC-treated patients was 9.6% (Table 2). This thrombotic risk may be higher than anticipated because of patient selection and reporting bias in small case series. However, case reports are still valuable, because they capture APS patients who had rare catastrophic events after starting DOACS.<sup>41-43</sup>

Two of the largest studies published in low-risk APS populations have reported reassuring VTE recurrence rates with DOAC use. An

References         Study dasign         N         Treatment         Tendment					Edlow-up	Thromboeie	Recurrent history of	thrombosis by ATE, % (n/N)	Recurrent thror posit	nbosis by triple antibody ivity, % (n/N)
113         Retrospective         26         R. f.S. D.         Mean 19 mode         38 (1/26)         0 (0/13)         7.7 (1/13)         0 (0/19)         14           114         Retrospective         35         R. 33         Mean 19 mo         0 (0/35)         - (Excluded)         0 (0/35)         N R           114         Retrospective         35         R. 35         Mean 19 mo         0 (0/35)         - (Excluded)         0 (0/35)         N R           115         Retrospective         8         R. 7, A: 1         Mean 19 mo         0 (0/35)         0 (0/12)         0 (0/13)         0 (0/13)         0 (0/14)         N R           116         Registy         19         R: 17, D. 2;         Mean 36 mode         316 (6/19)         N R <th>References</th> <th>Study design</th> <th>z</th> <th>Treatment</th> <th>(range)</th> <th>(N/u) %</th> <th>+Hx</th> <th>-Hx</th> <th>+tAb</th> <th>-tAb</th>	References	Study design	z	Treatment	(range)	(N/u) %	+Hx	-Hx	+tAb	-tAb
114         Renospective         35         R: 7, A: 1         Median 10mo         0 (0/3) $0$ (0/3)         NR           43         Renospective         8         R: 3.35         Median 10mo         0 (0/3)         50 (1/2)         83.3 (5/6)         66.7 (2/3)         0 (0/1)           115         Renospective         8         R: 7, A: 1         Mean 19 mo         0 (0/3)         50 (1/2)         83.3 (5/6)         66.7 (2/3)         0 (0/1)           116         Registry         19         R: 17, D: 2;         Mean 19 mo         0 (0/6)         0 (0/2)         0 (0/1)         0 (0/1)         0 (0/1)         0 (0/1)         10 (0/1)	113	Retrospective	26	R: 15; D: 11: initial 6	Mean 19 mo (8-29)	3.8 (1/26)	0 (0/13)	7.7 (1/13)	0 (0/19)	14.3 (1/7)
43         Retrospective         8 $R:8$ $5:365 d^*$ $75$ (6/6) $50$ (1/2) $83.3$ (5/6) $667$ (2/3) $68$ 115         Retrospective         8 $R:7, X:1$ Mean 19 mo $0$ (0/6) $0$ (0/6) $0$ (0/2) $0$ (0/1) $0$ (0/1)           116         Registry         19 $R:17; D:2;$ Mean 23.3 mo $31.6 (6/19)$ NR         NR <td>114</td> <td>Retrospective</td> <td>35</td> <td>R: 35</td> <td>Median 10 mo (6-24)</td> <td>0 (0/35)</td> <td>— (Excluded)</td> <td>0 (0/35)</td> <td>NR</td> <td>NR</td>	114	Retrospective	35	R: 35	Median 10 mo (6-24)	0 (0/35)	— (Excluded)	0 (0/35)	NR	NR
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	43 115	Retrospective Retrospective	ωω	R: 8 R: 7; A: 1	5-365 d* Mean 19 mo (2-36)	75 (6/8) 0 (0/8)	50 (1/2) 0 (0/6)	83.3 (5/6) 0 (0/2)	66.7 (2/3) 0 (0/1)	80 (4/5) 0 (0/7)
	116	Registry	19	R: 17; D: 2; initial: 2	Mean 23.3 mo (1-84)	31.6 (6/19)†	NR	R	NR	NR
44         RCT         54         R: 54         210 d         0 (0/54)         - (Excluded)         0 (0/54)         0 (0/14)         0         0           118         Prospective/         23         R: 23; initiati         Mean 55.6         26.1 (6/23)         100 (3/3)         15 (3/20)         50 (1/2)         23           116,119         Prospective/         58         R: 49; A: 3;         Mean 55.6         26.1 (6/25); 5.8 /         25 (2/8) §         50 (1/2)         23         24         NR	117	Retrospective	23	R: 23; initial: 3	Median 20 mo	4.3 (1/23)	NR	NN	NR	NR
118         Prospective/ registry         2         R: 23; initial: (28-40)         Mean 35.6         26.1 (6/23)         100 (3/3)         15 (3/20)         50 (1/2)         23           116,119         Prospectivet         5         R: 49; A: 3;         Mean 32.1 mo         10.7 (6/56);5.8 /         25 (2/6)\$         8.3 (4/48)         25 (4/16)\$         26 (4/16)\$         26 (4/16)\$         26 (4/16)\$         26 (4/16)\$         26 (4/16)\$         21 (4/2)\$         21 (4/2)\$         23 (4/48)         25 (4/16)\$         26 (4/16)\$         26 (4/16)\$         26 (4/16)\$         26 (4/16)\$         26 (4/16)\$         26 (4/16)\$         26 (4/16)\$         26 (4/16)\$         26 (4/16)\$         26 (4/16)\$         26 (4/16)\$         26 (4/16)\$         26 (4/16)\$         26 (4/16)\$         20 (4/16)\$         26 (4/26)\$         26 (4/26)\$	44	RCT	54	R: 54	210 d	0 (0/54)	— (Excluded)	0 (0/54)	0 (0/14)	0% (0/40)
116,119       Prospectivet       56       R: 49; A: 3;       Mean 22.1 mo       10.7 (6/56);5.8/       25 (2/8)5       8.3 (4/49)       25 (4/16)5         120       Retrospective       24       NR       Median 31 mo       8.3 (2/24)       NR       NR       NR         121       Retrospective       24       NR       Median 31 mo       8.3 (2/24)       NR       NR       NR       NR         121       Retrospective       41       R: 29, A: 7;       Median 31 mo       8.3 (2/24)       NR       NR       NR       NR       NR         121       Retrospective       41       29; A: 7;       Median 48 mo       12.2 (5/41)       NR       NR       NR       NR       NR       NR         121       Retrospective       82       Mean 18.8 mo       12.2 (5/41)       NR       NR       NR       NR       NR         Crowther and       Prospective       82       R: 82       Mean 18.8 mo       4.9 (4/82);4.0/       20 (1/5)       3.9 (3/77)       - (0/0)       4         Legault 2018       82       R: 82       Mean 18.8 mo       4.9 (4/21)       7.9 (3/38)       12 (7/59)       - (0/0)         37       59       R: 85       Mean 569 d       12	118	Prospective/ registry	23	R: 23; initial: 6	Mean 35.6 (29-40)	26.1 (6/23)	100 (3/3)	15 (3/20)	50 (1/2)	23.8 (5/21)
120         Retrospective         24         NR         Median 31 mo         8.3 (2/24)         NR	116,119	Prospective‡	56	R: 49; A: 3; D: 4	Mean 22.1 mo (2-43)	10.7 (6/56);5.8/ 100 patient- vears	25 (2/8)§	8.3 (4/48)	25 (4/16)§	5 (2/40)
121       Retrospective       41       R: 29; A: 7;       Median 48 mo       12.2 (5/41)       NR       NR       NR       NR       NR         D: 5;       (14-62)       (14-62)       (14-62)       (14-62)       (14-62)       NR       NR       NR       NR       NR         Crowther and Prospective       82       R: 82       Mean 18.8 mo       4.9 (4/82);4.0/       20 (1/5)       3.9 (3/77)       - (0/0)       4         Legault 2018       Prospective       82       R: 82       Mean 18.8 mo       4.9 (4/82);4.0/       20 (1/5)       3.9 (3/77)       - (0/0)       4         Journal Legault 2018       Prospective       82       R: 59       Mean 569 d       12 (7/59)       19 (4/21)       7.9 (3/38)       12 (7/59)       16/06d       16/62(1/62)         37       RCT         59       R: 59       Mean 569 d       12 (7/59)       19 (4/21)       7.9 (3/38)       12 (7/59)       16/62(1/62)       16/62(1/62)       16/62(1/62)       16/62(1/62)       16/62(1/62)       16/62(1/62)       16/62(1/62)       12 (7/59)       16/62(1/62)       16/62(1/62)       16/62(1/62)       16/62(1/62)       16/62(1/62)       16/62(1/62)       16/62(1/62)       16/62(1/62)       16/62(1/62)       16/62(1/62)       16/62(1/62)	120	Retrospective	94	NR	Median 31 mo	8.3 (2/24)	NR	NR	NR	NR
Crowther and Legault 2018         Prospective         82         R: 82         Mean 18.8 mo         4.9 (4/82);4.0/         20 (1/5)         3.9 (3/77)         — (0/0)         4           Legault 2018         129.8 patient- years         129.8 patient- years         129.8 patient- years         20 (1/5)         3.9 (3/77)         — (0/0)         4           37         RCT           59         R: 59         Mean 569 d         12 (7/59)         19 (4/21)         7.9 (3/38)         12 (7/59)         -           37         RCT           59         R: 59         Mean 569 d         12 (7/59)         19 (4/21)         7.9 (3/38)         12 (7/59)         -           37         RCT           59         R: 59         Mean 569 d         12 (7/59)         19 (4/21)         7.9 (3/38)         12 (7/59)         -           37         Pooled: 9.6 (44/         Pooled: 19.0 (11/58)         Pooled: 12.3         (14/114)         (16/20)         (16/20)         (95% Cl, 4.9.12)         (15/20)         (95% Cl, 4.9.12)         (16/20)         (95% Cl, 4.9.12)         (16/20)         (95% Cl, 4.9.12)         (16/20)         (16/20)         (16/20)	121	Retrospective	41	R: 29; A: 7; D: 5; initial: 14	Median 48 mo (14-62)	12.2 (5/41)	N	N	N	Х
37 RCT   59 R: 59 Mean 569 d 12 (7/59) 19 (4/21) 7.9 (3/38) 12 (7/59) - Pooled: 12.3 Pooled 1 458) (95% Cl, (95% Cl, 10.9-30.9) Cl, 4.2-9.9) (14/114) (16/20 7.2-12.7) 7.2-12.7) 95% Cl, 10.9-30.9) Cl, 4.2-9.9) (95% Cl, 4.9-12 7.5-19.6)	Crowther and Legault 2018	Prospective	82	R: 82	Mean 18.8 mo	4.9 (4/82);4.0/ 129.8 patient- vears	20 (1/5)	3.9 (3/77)	(0/0) —	4.9 (4/82)
	37	RCT	20	R: 59	Mean 569 d	12 (7/59) Pooled: 9.6 (44/ 458) (95% Cl, 7.2-12.7)	19 (4/21) Pooled: 19.0 (11/58) (95% Cl, 10.9-30.9)	7.9 (3/38) Pooled: 6.5 (19/293) (95% Cl, 4.2-9.9)	12 (7/59) Pooled: 12.3 (14/114) (95% Cl, 7.5-19.6)	— (0/0) Pooled 10.0 (16/202) (95% CI, 4.9-12.5)

included in the thrombotic episodes.

A, apixaban; D, dabigatran; Hx, history; initial anticoagulant treatment with a DOAC; NR, not reported; R, rivaroxaban; RCT, randomized controlled trial; tAb, triple-positive antibody status; Tmt, treatment. \*Time to recurrence reported.

flncluded 2 patients on DOACs for primary prevention.

‡All patients switched to a DOAC after a minimum of 3 months and p-dimer <500 ng/mL. SOne patient with a recurrent VTE had both a history of ATE and triple antibody positivity. ||Reported based on an on-treatment per protocol analysis.

open-label trial evaluated 116 patients randomized to rivaroxaban or warfarin for secondary VTE prevention with a primary surrogate outcome of percentage change in endogenous thrombin potential. Patients with ATE or recurrent VTE were excluded. The endogenous thrombin potential was higher in the rivaroxaban group than in the warfarin group and did not reach the set non-inferiority threshold of <20% difference. Although underpowered for clinical events, it is reassuring that there were no thrombotic events or major bleeding reported after 210 days in 54 APS patients who received rivaroxaban.<sup>44</sup> A multicenter prospective cohort of 82 APS patients with a history of VTE were treated with rivaroxaban for secondary VTE prevention. No patients were triple positive, and 5 patients had a history of ATE. There were 4 thromboembolic events (2 cerebrovascular and 2 VTE) in 129.8 patient-years of follow-up, a rate similar to previous studies evaluating warfarin<sup>35,36,45</sup> (M. Crowther and K. Legault, written communication, 17 April 2018).

Unfortunately, there is an unacceptably high thrombotic rate reported among high-risk APS patients treated with DOACs. TRAPS (Trial on Rivaroxaban in AntiPhospholipid Syndrome) is a multicenter trial that evaluated rivaroxaban versus warfarin in 120 triple-positive patients with APS.<sup>37</sup> In the intention-to-treat analysis, there were significantly more thrombotic events in the rivaroxaban arm (14%) compared with the warfarin arm (0%), leading to early trial termination. There were 7 (12%) arterial events, including among patients with only a history of VTE.<sup>37</sup> The ASTRO-APS (Apixaban for Secondary Prevention of Thrombosis Among Patients with Antiphospholipid Syndrome) is an open-label randomized trial evaluating apixaban vs usual care for prevention of recurrent thrombosis after at least 6 months of initial anticoagulation (www.clinicaltrials.gov identifier NCT02295475). After enrolling the first 25 patients, a preplanned Data Safety Monitoring Board review recommended an increase from apixaban 2.5 mg twice daily to apixaban 5 mg twice daily. After a higher than expected rate of stroke in 5 subsequent patients, an unplanned Data Safety Monitoring Board review recommended changing the enrollment criteria to exclude patients with prior arterial thrombosis and to obtain brain magnetic resonance imaging prior to enrollment to exclude stroke or white matter changes disproportionate for age.<sup>46</sup>

### Management summary

While some of the data in lower-risk APS patients have been reassuring, recent and ongoing trials have reported an increased rate of thrombosis among APS patients receiving DOACS, particularly those with previous arterial disease or triple positivity. Based on the available evidence, we should be extremely cautious when using DOACs in patients with APS.

A recent guidance statement from the 14th International Congress on Antiphospholipid Antibodies Task Force recommends that warfarin remain the current standard of care.<sup>47</sup> DOACs may be considered when there is a known VKA allergy/intolerance or poor anticoagulant control. At the time of publication, there were not enough data for the task force to recommend DOACs in high-risk scenarios such as those with recurrent VTE while on anticoagulation or for APSrelated arterial thrombosis.<sup>47</sup>

I recommend long-term anticoagulation with a VKA to APS patients as the current standard of care, unless contraindications are present such as thrombocytopenia (platelet count  $<50 \times 10^{9}$ /L). Based on the available evidence, I would avoid the use of DOACs in known high-risk subgroups (eg, triple positivity or a history of arterial disease; Figure 1). There may be a role for DOACs for secondary VTE prevention in a carefully selected subgroup of low-risk APS patients, such as those with a single unprovoked VTE and low-risk antibody profile and no



Figure 1. My management approach for confirmed APS and unprovoked VTE.

history of arterial thrombotic disease or neurological symptoms possibly related to small-vessel arterial disease (Figure 1). However, given the limited evidence and possible risk of arterial thrombosis, a detailed patient discussion outlining the risks and benefits is warranted. Unlike the general VTE population where dose reduction of DOACs may be an option after 6 months of initial anticoagulation,<sup>48,49</sup> in APS patients, I would follow the product monographs and not recommend dose reduction of DOACs due to the absence of data and potential for recurrent thrombosis. Further research is still needed.

### Other management scenarios in APS

*ATE.* For patients presenting with an initial ATE, I use a VKA with an INR target of 2 to 3 instead of antiplatelet therapy or a higher INR target.<sup>50,51</sup> I counsel all patients with APS on cardiovascular risk factor management.

*Recurrent breakthrough thrombosis.* If an APS patient had recurrent VTE while on therapeutic anticoagulation with warfarin (INR 2-3), I would use a short course of therapeutic LMWH until clinical improvement (eg, 3-4 weeks) and add aspirin to long-term VKA therapy. Alternative options for managing recurrent thrombosis on therapeutic anticoagulation include targeting a higher INR of 3 to 4, choosing an alternative long-term anticoagulant such as LMWH, or adding agents such as hydroxychloroquine or statins based on limited evidence.<sup>1</sup>

*Catastrophic APS.* A combination of glucocorticoids, therapeutic UFH and plasmapharesis or IV immune globulin is recommended as first-line therapy for catastrophic APS based on a recent guidance document.<sup>12</sup> The addition of an antiplatelet agent may also be considered based on the clinical situation.<sup>12</sup>

*Prophylaxis in high-risk settings.* Patients with APS may require additional prophylaxis in high-risk settings such as pregnancy or around surgery. In pregnant patients with a previous VTE, I recommend intermediate to therapeutic doses of LMWH during pregnancy.<sup>52</sup> In APS patients with past ATE, I recommend therapeutic doses of LMWH in pregnancy, with or without aspirin, based

on the clinical scenario. Postpartum, APS patients with past thrombosis should resume LMWH until transitioned back to warfarin, with a LMWH dose that takes into account the initial bleeding risk postpartum and a patient's individual thrombotic risk. Among patients with obstetrical APS with no past thrombosis, the risk of VTE during pregnancy is reassuringly low, and antepartum LMWH would not be needed.<sup>53</sup> The use of antepartum LMWH and aspirin to prevent recurrent pregnancy loss is based on studies that report mixed results and have variable definitions of APS, so a patient discussion about the risks and benefits is needed.<sup>54-56</sup> I recommend postpartum prophylactic-dose LMWH for obstetrical APS patients with high-risk antibody profiles (eg, titers >40 GPL/MPL or multiple antibody positivity) or if additional risk factors such as systemic lupus erythematosus are present and then have a preferencesand values-based patient discussion about prophylaxis for APS patients with lower-risk features.53

There are limited data for the use of anticoagulant "bridging" among APS patients when their anticoagulation is held in the perioperative setting. A retrospective cohort of 416 patients on warfarin for past VTE reported a low VTE incidence (0.32%) with minimal to no use of LMWH, and over 38% of patients tested had a high-risk thrombophilia present that included LAC or aCL positivity.<sup>57</sup> For APS patients with past thrombosis, I typically use prophylactic doses of LMWH before and after surgery instead of therapeutic doses in order to minimize bleeding risk. Postoperative bleeding from anticoagulation can be associated with thrombosis, particularly when anticoagulants are held for a prolonged period of time due to bleeding complications.<sup>57,58</sup>

### HIT

### HIT and the risk of thrombosis

HIT is a "clinicopathologic" syndrome with clinical manifestations that are supported by serological and functional laboratory assays. HIT typically presents with a platelet count drop  $\geq$ 50% ~5 to 10 days after UFH/LMWH exposure ( $\leq$ 1 day if recent heparin exposure) and is associated with VTE and ATE and less commonly limb gangrene, heparininduced skin lesions, and anaphylactoid reactions to heparin.<sup>2,59,60</sup> VTE is more common than ATE (4:1), and unusual site thrombosis is possible including adrenal hemorrhage from presumed adrenal vein thrombosis.<sup>61,62</sup> IgG antibodies recognize platelet factor 4 (PF4)/ heparin complexes on the surface of platelets, which can activate platelets, monocytes and endothelial cells and lead to clinical HIT in a proportion of cases.<sup>2,63</sup> There is an imbalance between pro- and

Table 3. 4	4T score	HIT	clinical	scoring	system
------------	----------	-----	----------	---------	--------

anticoagulants, and the addition of warfarin in acute HIT can lead to venous limb gangrene because of an acquired protein C deficiency.<sup>64-66</sup> Several variants of HIT have been described where anti-PF4 antibodies recognize PF4/polyanion complexes without heparin present and include spontaneous HIT (development in the absence of heparin), persistent HIT (where HIT takes several weeks to recover), and delayed-onset HIT (where HIT begins or worsens after stopping heparin).<sup>67</sup>

The clinical 4T score helps clinicians recognize possible HIT, where an intermediate or high probability 4T score  $\geq$ 4 requires further laboratory testing<sup>68</sup> (Table 3). Antibody-based enzyme immunoassay (EIA) testing is highly sensitive and can help to rule out HIT if the result is negative. Functional testing such as the serotonin release assay (SRA) is sensitive and specific and can confirm HIT if the result is positive and the clinical picture fits.<sup>59,68-70</sup> If a patient has an intermediate to high pretest probability of HIT, then a positive EIA test result with a high optical density can limit SRA testing due to improved EIA specificity.<sup>71,72</sup>

Historically, the risk of thrombosis was 38% to 53% in the first 30 days of HIT with a high mortality rate when another anticoagulant was not initiated.<sup>62,73</sup> In a recent retrospective study across US centers that evaluated patients until hospital discharge or day 45, the thrombotic risk was ~20% among patients with a positive EIA test result despite the majority being on a nonheparin anticoagulant.<sup>74</sup>

### Anticoagulant management in HIT

Several possible anticoagulant options exist for treatment of both HIT with thrombosis (HIT-T) or without thrombosis (isolated HIT). Argatroban and danaparoid are approved for the treatment of HIT, and bivalirudin is approved for treatment of HIT for patients undergoing percutaneous coronary intervention. Danaparoid is not available in the United States. Fondaparinux and desirudin are "off label" for the treatment of HIT but have data to support their use.

There is reasonably strong data to support the use of fondaparinux in the treatment of HIT. Fondaparinux is an indirect factor Xa inhibitor that has proven efficacy in the treatment of other conditions such as VTE and acute coronary syndromes. Fondaparinux is given by subcutaneous injection and does not affect the PTT and may provide more stable dosing in severe HIT where coagulation parameters can be abnormal at baseline. The development of heparin antibodies that

	2 points	1 point	0 points
Thrombocytopenia	Platelet count fall >50% and platelet count nadir $\ge$ 20 $\times$ 10 <sup>9</sup> /L	Platelet count fall 30-50% or platelet count nadir 10-19 $ imes$ 10 <sup>9</sup> /L	Platelet count fall <30% or platelet count nadir < $10 \times 10^9/L$
Timing of platelet count fall	Clear onset of thrombocytopenia 5-10 d after heparin administration or platelet count fall ≤1 d with prior heparin exposure within 30 d	Timing is consistent with a day 5-10 platelet count fall but is not clear (eg, missing platelet counts), onset after day 10, or fall ≤1 d with prior heparin exposure 30-100 d ago	Platelet count fall is <4 d without recent heparin exposure
Thrombosis or other sequelae	Confirmed evidence of a new thrombosis, skin necrosis (lesions at heparin injection site, or acute systemic reaction after IV unfractionated heparin bolus	Suspected (but not proven) thrombosis, progressive or recurrent thrombosis, or nonnecrotizing skin lesions	None
Other causes of thrombocytopenia	None apparent	Possible	Definite

The scoring system is categorized as low probability (0-3 points), intermediate probability (4-5 points), or high probability (6-8 points). Adapted from Lo et al<sup>59</sup> with permission.

cross-react to fondaparinux is exceedingly rare (3 cases reported)<sup>75-77</sup>; autoimmune HIT or an alternative diagnosis should be considered if the platelet count does not recover after fondaparinux is initiated.

There are reports of 95 patients with likely HIT who received fondaparinux and have not had a new or progressive thrombosis.<sup>78-85</sup> It is possible that this group represents a selected population where clinicians were comfortable using nonstandard treatment. Reassuringly, there was no difference between the thrombotic risk reported in 133 patients treated with fondaparinux (16.5%) compared with those treated with argatroban and danaparoid (21.4%) when patients were matched using propensity scoring for age, sex, creatinine, 4T score, and comorbidity index.<sup>86</sup> Table 4 reviews drug characteristics of fondaparinux and other standard HIT treatments

The DOACs are attractive for use in HIT because they have a quick onset of action, do not lower protein C levels, and are not known to cause antibodies. Linkins et al<sup>87</sup> completed a prospective study of 12 HIT patients treated with rivaroxaban. The thrombotic rate was 4.5% (95% CI, 0% to 23%) and included 1 patient with an extension of a line-associated upper extremity VTE that was treated with catheter removal and rivaroxaban continuation. One patient had worsening of bilateral lower limb arterial thrombosis requiring amputation while on rivaroxaban. Subsequently, Warkentin et al<sup>88</sup> reported 16 additional HIT patients who were treated with rivaroxaban for HIT-T (all were VTE events) or isolated HIT. There were no new thrombotic events, and no major bleeding, limb amputation, or death occurred in 3 months of follow-up. Warkentin et al completed a systematic review of probable HIT patients (4T score  $\geq 4$  and detection of HIT antibodies or 4T score  $\geq 6$ ) treated with DOACs prior to platelet recovery, and the risk of new thrombosis was 2.6% (2/81).<sup>88,89</sup> There were 11 additional HIT patients who transitioned to a DOAC after platelet count recovery with no new thrombosis and 1 major bleeding event in a patient with known varices.<sup>88</sup> The limitation of these studies included a selected patient population where DOACs were deemed appropriate, and few HIT patients had an initial ATE.

### Management summary

Because of the high risk of thrombosis, once HIT is suspected based on clinical suspicion (eg, 4T score  $\geq$ 4), then heparin should be

Table 4. Parental anticoagulants for the management of HIT

stopped and a therapeutic nonheparin anticoagulant started until confirmatory laboratory testing is completed. If I have decided to send off laboratory testing but clinically think the patient has a relatively low likelihood of HIT and am concerned for bleeding from another cause of thrombocytopenia, then I use prophylactic doses of fondaparinux (2.5 mg subcutaneously daily) until confirmatory test results come back, a practice that is based on expert opinion and limited evidence.<sup>69,86,90</sup>

While different HIT guidelines consistently recommend starting a nonheparin anticoagulant once HIT is suspected, the choice of anticoagulant varies according to the guideline (differences outlined by Wang et al<sup>91</sup>). My current practice is to use therapeutic-dose fondaparinux in the acute setting of HIT-T and isolated HIT; if the patient has renal failure or requires an urgent procedure, then I use argatroban, and if the patient is undergoing cardiac surgery, then I prefer to use bivalirudin (Figure 2). It is my practice to screen all positive HIT patients with bilateral leg ultrasounds given the high risk of thrombosis. I would avoid inferior vena cava filter placement, which can be highly prothrombotic in HIT.<sup>92</sup> I have not been using DOACs in the upfront setting, as this is the most prothrombotic period that includes ATE,<sup>62,74</sup> and many of hospitalized patients cannot tolerate oral anticoagulation. When the patient is closer to discharge from hospital, I consider switching to a DOAC after a careful patient discussion, particularly when thrombosis is absent or if their VTE is clinically improving. If I am worried about progressive or recurrent VTE, or if the patient had an ATE, then I would overlap the nonheparin anticoagulant with VKA for a minimum of 5 days once the platelet count is  $>150 \times 10^{9}/L$ because of the risk of hypercoaguability from acquired protein C deficiency from VKA.

I would treat HIT-T with anticoagulation for 3 months, because it is a provoked VTE. While controversial,<sup>74,93</sup> I treat patients with isolated HIT for 3 months based on the fact that other known thrombotic risk factors extend outward to 3 months and HIT antibodies can be present for ~100 days (functional test, median 50 days; EIA test, median 85-90 days).<sup>60,94</sup> The majority of guidelines recommend 4 weeks duration of anticoagulation in isolated HIT.<sup>91</sup> If there were risk factors for bleeding in a patient with isolated HIT, then I would stop anticoagulation at ~4 weeks.<sup>62,73</sup>

	Indirect factor Xa inhibitors		Direct thrombin inhibitors			
	Fondaparinux	Danaparoid	Argatroban	Bivalirudin	Desirudin	
Administration	Subcutaneous injection	IV infusion or subcutaneous injection	Continuous IV infusion	Continuous IV infusion	Subcutaneous injection	
Clearance (half-life)	Renal (17 h)	Renal (24 h)	Hepatobiliary (40-50 min)	Renal/enzymatic (25 min)	Renal (2 h)	
INR interference	No	No	Yes	Yes	Possible	
Drug monitoring	None*	Anti-Xa activity*	PTT	PTT	None	
Reversal agent	None†	None†	None	None	None	
Other	Caution with renal impairment. Contraindicated with CrCl <30 mL/min	Caution with renal impairment; not available in the United States	Caution with liver dysfunction; consider dose reduction in critically ill patients	Evidence for use available in cardiac surgery and PCI	Caution with rena	

CrCl, creatinine clearance; PCl, percutaneous coronary intervention.

\*Some centers monitor fondaparinux using fondaparinux-specific anti-Xa activity. Some centers do not routinely monitor danaparoid, particularly in patients with normal renal function.<sup>93</sup>

+Andexanet alfa is a reversal agent for direct and indirect Xa inhibitors but has not been studied or approved for use in HIT or with reversal of fondaparinux or danaparoid. Given the potential risk of ischemic events with andexanet alfa, caution in HIT is needed.



Figure 2. My management approach for suspected or confirmed HIT.

### Other management scenarios in HIT

*Future anticoagulation use.* For patients with confirmed HIT who require anticoagulation in the future, I recommend a nonheparin anticoagulant such as fondaparinux or a DOAC depending on the clinical scenario.

*Cardiac surgery.* The ACCP guidelines recommend the use of bivalirudin over other nonheparin anticoagulants or heparin plus antiplatelet agents for HIT patients requiring cardiac surgery.<sup>95</sup> When possible, cardiac surgery should be delayed until HIT test results are negative. If it is not possible to delay surgery, then an alternative anticoagulant should be used if the EIA and SRA test results are still positive. The evidence for bivalirudin is based on prospective cohort studies in HIT patients and randomized controlled trial data in non-HIT patients,<sup>95</sup> with protocols available on and off bypass.<sup>96,97</sup> If the positive functional SRA test result subsequently becomes negative, then short exposure to heparin during the procedure is possible, with a nonheparin anticoagulant used postoperatively.<sup>93</sup> Plasma exchange to remove HIT antibodies or IV immune globulin are alternative strategies that have been reported in positive HIT patients who are refractory to standard therapy or require urgent surgery.<sup>98-100</sup>

### PNH

### PNH and the risk of thrombosis

PNH is a rare "orphan" disease that affects 1 to 2 patients in 1 million and is characterized by intravascular hemolysis, thrombosis, immunemediated bone marrow failure, and other symptoms related to smooth muscle dysfunction. A somatic mutation in the *PIGA* (phosphatidylinositol glycan complement class A) gene in hematopoietic stem cells leads to the absence of glycosylphosphatidylinositol (GPI) anchor proteins on the surface of progeny blood cells. Two important GPIlinked complement regulatory proteins, CD55 and CD59, are reduced or absent on red blood cells, which leads to complement-mediated hemolysis. The pathophysiology of thrombosis is multifactorial due to increased procoagulant microparticles, endothelial cell damage from free hemoglobin, nitric oxide depletion, complement-mediated platelet, neutrophil and monocyte activation, and absence of other GPI anchor proteins that affect the coagulation and fibrinolytic system.<sup>3,101</sup>

The cumulative thrombotic risk in PNH is ~20% to 30% over 10 years and is associated with a high mortality rate.<sup>102-104</sup> Patients with a large PNH granulocyte clone (>50%-60%) have a higher thrombotic risk (35%-54%) than those with a smaller clone (6%-17%).<sup>104-106</sup> VTE is more common than ATE and includes a high proportion of unusual site thrombosis, including mesenteric and hepatic vein thrombosis.<sup>107,108</sup> Approximately 5% to 10% of PNH patients will present with thrombosis.<sup>103,104</sup> Screening all patients with unprovoked VTE for PNH is unnecessary and should be reserved for those presenting with unusual site thrombosis or atypical features such as hemolysis or anemia.<sup>109</sup> The incidence of HIT is reportedly increased among PNH patients secondary to increased platelet activation with induced release of PF4.<sup>110</sup>

The introduction of effective complement blockade with eculizumab, a humanized monoclonal antibody against complement protein C5, has decreased the risk of thrombosis in patients with PNH. In a pooled analysis of 3 extension trials that enrolled 195 patients with PNH and clinically meaningful hemolytic disease (history of VTE/ ATE in 32% of participants; anticoagulant use in 56% of participants), the overall thrombotic rate was reduced from 7.37% per person-year to 1.07% per person-year. Among only the patients on anticoagulation, the thrombotic rate was reduced from 10.61% per person-year to 0.62% per person-year.<sup>107</sup> There are only a small number of reports of patients who have successfully stopped anticoagulation after their disease was controlled on eculizumab.<sup>111</sup>

### Anticoagulant management in PNH

In a patient with a new VTE or ATE, I recommend starting LMWH and transitioning to a VKA. I would treat for a minimum of 3 to

6 months and as long as the underlying disease is active, unless a contraindication such as significant thrombocytopenia (platelet count  $<50 \times 10^{9}$ /L) is present. What to do for patients with previous thrombosis who have stable disease on eculizumab is still unknown and warrants a detailed patient discussion about the risks and benefits of anticoagulation.<sup>110</sup> Given the lack of evidence, I typically recommend continuing some form of anticoagulation but acknowledge the importance of patient preference and the possibility of stopping anticoagulation.

DOAC use in PNH is an "evidence-free zone." There is 1 published case report of a PNH patient with a history of cerebral vein thrombosis who was switched to rivaroxaban after the patient's hemolysis stabilized on eculizumab.<sup>112</sup> Based on extrapolated data and a patient discussion, I would consider a DOAC only for secondary VTE prevention if the patient had controlled disease on eculizumab. I would not use a DOAC if there was recurrent VTE, past ATE, or unusual site thrombosis or if the patient's underlying PNH was uncontrolled given the lack of evidence and possibility of harm.

### Other management scenarios in PNH

*Prophylaxis use.* Because eculizumab has greatly mitigated the risk of thrombosis in PNH, I would not recommend primary prophylaxis in patients who are on eculizumab. Among PNH patients who are not on eculizumab, the role of primary prophylaxis is controversial and must be balanced against the risk of bleeding.<sup>110</sup> In situations that carry additional thrombotic risk, such as in pregnancy or in the perioperative setting, prophylactic anticoagulation with LMWH may be warranted with dosing that reflects bleeding risk (thrombocytopenia) and thrombotic risk (status of underlying disease).

### Conclusion

Based on limited data, DOAC use may be possible in a carefully selected subgroup of low-risk patients with APS, HIT, and PNH, especially after an initial treatment course of LMWH/VKA (APS and PNH) or a nonheparin anticoagulant such as fondaparinux (HIT). DOACs should generally be avoided in high-risk subgroups, including those with past ATE, recurrent VTE, or evidence of active underlying disease (eg, triple positivity in APS, thrombocytopenia in HIT, or active hemolysis/large clone in PNH) until further research is completed.

### Correspondence

Leslie Skeith, Room C210, Foothills Medical Centre, 1403 29th St NW, Calgary, AB T2N 2T9, Canada; e-mail: laskeith@ucalgary.ca.

### References

- 1. Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. *N Engl J Med.* 2018;378(21):2010-2021.
- Warkentin TE, Sheppard JA, Moore JC, Cook RJ, Kelton JG. Studies of the immune response in heparin-induced thrombocytopenia. *Blood*. 2009;113(20):4963-4969.
- Van Bijnen STA, Van Heerde WL, Muus P. Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria. *J Thromb Haemost*. 2012;10(1):1-10.
- Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor. *J Thromb Haemost.* 2005;3(3):514-521.
- Donnellan E, Kevane B, Bird BRH, Ainle FN. Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management. *Curr Oncol.* 2014;21(3):134-143.
- van Es N, Louzada M, Carrier M, et al. Predicting the risk of recurrent venous thromboembolism in patients with cancer: A prospective cohort study. *Thromb Res.* 2018;163:41-46.

- Raskob GE, van Es N, Verhamme P, et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. *N Engl J Med.* 2018;378(7):615-624.
- Li A, Garcia DA, Lyman GH, Carrier M. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and metaanalysis [published online ahead of print 2 March 2018]. *Thromb Res.* doi:10.1016/j.thromres.2018.02.144.
- Young A, Marshall A, Thirlwall J, et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D<sup>™</sup> pilot trial [abstract]. *Blood*. 2017; 130(suppl 1). Abstract 625.
- Chaturvedi S, McCrae KR. Diagnosis and management of the antiphospholipid syndrome. *Blood Rev.* 2017;31(6):406-417.
- Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb Haemost*. 2006;4(2): 295-306.
- Legault K, Schunemann H, Hillis C, et al. McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. *J Thromb Haemost.* 2018;16(8):1-9.
- Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. *Blood*. 2003;101(5):1827-1832.
- Reynaud Q, Lega JC, Mismetti P, et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and metaanalysis. *Autoimmun Rev.* 2014;13(6):595-608.
- Urbanus RT, de Groot PG. Antiphospholipid antibodies—we are not quite there yet. *Blood Rev.* 2011;25(2):97-106.
- Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. *Blood.* 2003;102(8):2717-2723.
- de Laat B, Pengo V, Pabinger I, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. *J Thromb Haemost*. 2009;7(11):1767-1773.
- de Laat B, Derksen RHWM, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. *Blood.* 2005;105(4):1540-1545.
- Girón-González JA, García del Río E, Rodríguez C, Rodríguez-Martorell J, Serrano A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol. 2004;31(8):1560-1567.
- Mustonen P, Lehtonen KV, Javela K, Puurunen M. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study. *Lupus*. 2014; 23(14):1468-1476.
- Pengo V, Testa S, Martinelli I, et al. Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. *Thromb Res.* 2015;135(1):46-49.
- Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. *Blood*. 2011;118(17): 4714-4718.
- Galli M, Borrelli G, Jacobsen EM, et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. *Blood.* 2007;110(4):1178-1183.
- Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. *Blood*. 1995;86(10):3685-3691.
- Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. *N Engl J Med.* 1999;340(12):901-907.
- Schulman S, Svenungsson E, Granqvist S; Duration of Anticoagulation Study Group. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. *Am J Med.* 1998;104(4):332-338.

Downloaded from http://ashpublications.net/hematology/article-pdf/2018/1/439/1252329/hem01861.pdf by guest on 17 May 2024

- Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. *N Engl J Med.* 1995;332(15):993-997.
- Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. *Ann Intern Med.* 1992;117(4):303-308.
- Garcia D, Akl EA, Carr R, Kearon C. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. *Blood.* 2013;122(5):817-824.
- Kearon C, Parpia S, Spencer FA, et al. Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. *Blood.* 2018;131(19):2151-2160.
- Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8(2):237-242.
- 32. Kearon C, Iorio A, Palareti G; Subcommittee on Control of Anticoagulation of the SSC of the ISTH. Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting. J Thromb Haemost. 2010;8(10):2313-2315.
- Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: casefatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. *Ann Intern Med.* 2010;152(9):578-589.
- 34. Rodger MA, Le Gal G, Anderson DR, et al; REVERSE II Study Investigators. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. *BMJ*. 2017;356:j1065.
- 35. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349(12):1133-1138.
- 36. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). *J Thromb Haemost.* 2005;3(5):848-853.
- Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. *Blood*. 2018; 132(13):1365-1371.
- 38. Goldhaber SZ, Eriksson H, Kakkar A, et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™. Vasc Med. 2016;21(6):506-514.
- 39. Dufrost V, Risse J, Zuily S, Wahl D. Direct oral anticoagulants use in antiphospholipid syndrome: Are these drugs an effective and safe alternative to warfarin? A systematic review of the literature. *Curr Rheumatol Rep.* 2016;18(12):74.
- Yazici A, Unlu O, Erkan D. Comment on: "The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome". *Thromb Res.* 2017;157:82-83.
- Crowley MP, Cuadrado MJ, Hunt BJ. Catastrophic antiphospholipid syndrome on switching from warfarin to rivaroxaban. *Thromb Res.* 2017;153:37-39.
- Rokos J, Heger M, Stöllberger C, Finsterer J, Laufer G, Wiedemann D. Bipolar disorder, ischemic stroke, mitral valve vegetation and recurrent venous thrombosis due to antiphospholipid syndrome despite rivaroxaban. *Int J Cardiol.* 2016;221:383-384.
- Signorelli F, Nogueira F, Domingues V, Mariz HA, Levy RA. Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. *Clin Rheumatol.* 2016;35(3): 801-805.
- 44. Cohen H, Hunt BJ, Efthymiou M, et al; RAPS trial investigators. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. *Lancet Haematol.* 2016;3(9):e426-e436.
- 45. Unlu O, Andrade D, Banzato A, et al. Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking (APS ACTION)

- 46. Woller SC, Stevens SM, Kaplan DA, T Rondina M. Protocol modification of apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome study. *Clin Appl Thromb Hemost.* 2018;24(1):192.
- Erkan D, Aguiar CL, Andrade D, et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. *Autoimmun Rev.* 2014;13(6):685-696.
- Agnelli G, Buller HR, Cohen A, et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. *N Engl J Med.* 2013;368(8):699-708.
- 49. Weitz JI, Lensing AWA, Prins MH, et al; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. *N Engl J Med.* 2017;376(13):1211-1222.
- 50. Bala MM, Celinska-Lowenhoff M, Szot W, et al. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. *Cochrane Database Syst Rev.* 2017;10:CD012169.
- 51. Jackson WG, Oromendia C, Unlu O, Erkan D, DeSancho MT; Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking. Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy. *Blood Adv.* 2017;1(25):2320-2324.
- Bates SM, Middeldorp S, Rodger M, James AH, Greer I. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. *J Thromb Thrombolysis*. 2016;41(1):92-128.
- Skeith L. Preventing venous thromboembolism during pregnancy and postpartum: Crossing the threshold. *Hematology*. 2017;2017:160–167.
- 54. Skeith L, Rodger M. Anticoagulants to prevent recurrent placentamediated pregnancy complications: Is it time to put the needles away? *Thromb Res.* 2017;151(suppl 1):S38-S42.
- 55. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012;141(2 suppl):e691S-e736S.
- Chan W-S, Rey E, Kent NE, et al; Society of Obstetricians and Gynecologists of Canada. Venous thromboembolism and antithrombotic therapy in pregnancy. J Obstet Gynaecol Can. 2014;36(6):527-553.
- Skeith L, Taylor J, Lazo-Langner A, Kovacs MJ. Conservative perioperative anticoagulation management in patients with chronic venous thromboembolic disease: a cohort study. *J Thromb Haemost.* 2012; 10(11):2298-2304.
- Kovacs MJ, Kearon C, Rodger M, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. *Circulation*. 2004;110(12):1658-1663.
- Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparininduced thrombocytopenia in two clinical settings. *J Thromb Haemost*. 2006;4(4):759-765.
- Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344(17):1286-1292.
- Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332(20):1330-1335.
- 62. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. *Am J Med.* 1996;101(5):502-507.
- Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparininduced thrombocytopenia. *Blood.* 2000;96(5):1703-1708.
- Greinacher A. Heparin-induced thrombocytopenia. N Engl J Med. 2015; 373(3):252-261.
- Warkentin TE. Ischemic limb gangrene with pulses. N Engl J Med. 2015;373(7):642-655.

- 66. Kowalska MA, Krishnaswamy S, Rauova L, et al. Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HIT. *Blood*. 2011;118(10):2882-2888.
- 67. Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. *J Thromb Haemost*. 2017;15(11):2099-2114.
- Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. *Blood.* 2012;120(20):4160-4167.
- Warkentin TE. How I diagnose and manage HIT. Hematology Am Soc Hematol Educ Program. 2011;2011:143-149.
- Nagler M, Bachmann LM, ten Cate H, ten Cate-Hoek A. Diagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis. *Blood.* 2016;127(5): 546-557.
- Raschke RA, Curry SC, Warkentin TE, Gerkin RD. Improving clinical interpretation of the anti-platelet factor 4/heparin enzyme-linked immunosorbent assay for the diagnosis of heparin-induced thrombocytopenia through the use of receiver operating characteristic analysis, stratum-specific likelihood ratios, and Bayes theorem. *Chest.* 2013; 144(4):1269-1275.
- Chan CM, Woods CJ, Warkentin TE, Sheppard JI, Shorr AF. The role for optical density in heparin-induced thrombocytopenia. *Chest.* 2015; 148(1):55-61.
- Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. *Am J Med.* 1999;106(6):629-635.
- Kuter DJ, Konkle BA, Hamza TH, et al. Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia. *Am J Hematol.* 2017; 92(8):730-738.
- 75. Tvito A, Bakchoul T, Rowe JM, Greinacher A, Ganzel C. Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment. *Am J Hematol.* 2015;90(7):675-678.
- Poudel DR, Ghimire S, Dhital R, Forman DA, Warkentin TE. Spontaneous HIT syndrome post-knee replacement surgery with delayed recovery of thrombocytopenia: a case report and literature review. *Platelets*. 2017;28(6):614-620.
- 77. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia. *Thromb Haemost*. 2016;116(5):813-822.
- Warkentin TE. Fondaparinux for treatment of heparin-induced thrombocytopenia: too good to be true? J Am Coll Cardiol. 2017; 70(21):2649-2651.
- Warkentin TE, Pai M, Sheppard JI, Schulman S, Spyropoulos AC, Eikelboom JW. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. *J Thromb Haemost.* 2011;9(12):2389-2396.
- Kuo KH, Kovacs MJ. Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. *Thromb Haemost.* 2005; 93(5):999-1000.
- Goldfarb MJ, Blostein MD. Fondaparinux in acute heparin-induced thrombocytopenia: a case series. *J Thromb Haemost.* 2011;9(12): 2501-2503.
- Schindewolf M, Steindl J, Beyer-Westendorf J, et al. Use of fondaparinux off-label or approved anticoagulants for management of heparininduced thrombocytopenia. J Am Coll Cardiol. 2017;70(21):2636-2648.
- Lobo B, Finch C, Howard A, Minhas S. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. *Thromb Haemost.* 2008;99(1):208-214.
- Grouzi E, Kyriakou E, Panagou I, Spiliotopoulou I. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a singlecenter experience. *Clin Appl Thromb Hemost.* 2010;16(6):663-667.
- Warkentin TE, Davidson BL, Büller HR, et al. Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. *Chest.* 2011;140(2):366-373.
- Kang M, Alahmadi M, Sawh S, Kovacs MJ, Lazo-Langner A. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. *Blood.* 2015;125(6):924-929.

- Linkins LA, Warkentin TE, Pai M, et al. Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study. *J Thromb Haemost.* 2016;14(6):1206-1210.
- Warkentin TE, Pai M, Linkins LA. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. *Blood.* 2017;130(9):1104-1113.
- Davis KA, Davis DO. Direct acting oral anticoagulants for the treatment of suspected heparin-induced thrombocytopenia. *Eur J Haematol.* 2017;99(4):332-335.
- Linkins LA, Bates SM, Lee AYY, Heddle NM, Wang G, Warkentin TE. Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study. *Blood.* 2015;126(5):597-603.
- Wang Y, Ye ZK, Li JF, Cui XL, Liu LH. Heparin-induced thrombocytopenia: a critical appraisal of clinical practice guidelines with the AGREE II instrument. *Thromb Res.* 2018;166:10-18.
- Hong AP, Cook DJ, Sigouin CS, Warkentin TE. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. *Blood.* 2003;101(8): 3049-3051.
- 93. Cuker A. Management of the multiple phases of heparin-induced thrombocytopenia. *Thromb Haemost.* 2016;116(5):835-842.
- Mattioli AV, Bonetti L, Zennaro M, Ambrosio G, Mattioli G. Heparin/ PF4 antibodies formation after heparin treatment: temporal aspects and long-term follow-up. *Am Heart J.* 2009;157(3):589-595.
- 95. Linkins L-A, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia. *Chest.* 2012;141(2 suppl): e495S-e530S.
- 96. Dyke CM, Smedira NG, Koster A, et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. *J Thorac Cardiovasc Surg.* 2006;131(3):533-539.
- Koster A, Spiess B, Jurmann M, et al. Bivalirudin provides rapid, effective, and reliable anticoagulation during off-pump coronary revascularization: results of the "EVOLUTION OFF" trial. *Anesth Analg.* 2006;103(3):540-544.
- Warkentin TE, Climans TH, Morin P-A. Intravenous immune globulin to prevent heparin-induced thrombocytopenia. *N Engl J Med.* 2018; 378(19):1845-1848.
- 99. Ramu B, Cogswell RJ, Reding MT, John R, Martin CM. Plasma exchange to remove heparin-induced thrombocytopenia antibodies and the use of heparin during cardiopulmonary bypass in critically ill cardiac patients. *J Heart Lung Transplant*. 2018;37(8):1038-1040.
- Padmanabhan A, Jones CG, Pechauer SM, et al. IVIg for treatment of severe refractory heparin-induced thrombocytopenia. *Chest.* 2017; 152(3):478-485.
- Peacock-Young B, Macrae FL, Newton DJ, Hill A, Ariëns RAS. The prothrombotic state in paroxysmal nocturnal hemoglobinuria: a multifaceted source. *Haematologica*. 2018;103(1):9-17.
- Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. *N Engl J Med.* 1995;333(19): 1253-1258.
- 103. de Latour RP, Mary JY, Salanoubat C, et al; French Association of Young Hematologists. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. *Blood.* 2008;112(8): 3099-3106.
- Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). *Blood.* 2003;102(10):3587-3591.
- 105. Moyo VM, Mukhina GL, Garrett ES, Brodsky RA. Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. Br J Haematol. 2004;126(1):133-138.
- 106. Schrezenmeier H, Muus P, Socié G, et al. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. *Haematologica*. 2014;99(5):922-929.
- 107. Hillmen P, Muus P, Dührsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. *Blood*. 2007;110(12):4123-4128.

- Ziakas PD, Poulou LS, Rokas GI, Bartzoudis D, Voulgarelis M. Thrombosis in paroxysmal nocturnal hemoglobinuria: sites, risks, outcome. An overview. J Thromb Haemost. 2007;5(3):642-645.
- Lazo-Langner A, Kovacs MJ, Hedley B, et al. Screening of patients with idiopathic venous thromboembolism for paroxysmal nocturnal hemoglobinuria clones. *Thromb Res.* 2015;135(6):1107-1109.
- Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. *Blood*. 2013;121(25):4985-4996, quiz 5105.
- 111. Emadi A, Brodsky RA. Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2009;84(10):699-701.
- 112. Dragoni F, Chiarotti F, Lombardi L, Iori AP, Cafolla A. Anticoagulant therapy with rivaroxaban in a young patient with paroxysmal nocturnal hemoglobinuria. *Clin Case Rep.* 2015;3(10): 790-792.
- 113. Noel N, Dutasta F, Costedoat-Chalumeau N, et al. Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. *Autoimmun Rev.* 2015;14(8):680-685.
- Sciascia S, Breen K, Hunt BJ. Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism. *Blood Coagul Fibrinolysis*. 2015;26(4):476-477.

- 115. Betancur JF, Bonilla-Abadía F, Hormaza AA, Jaramillo FJ, Cañas CA, Tobón GJ. Direct oral anticoagulants in antiphospholipid syndrome: a real life case series. *Lupus*. 2016;25(6):658-662.
- Malec K, Góralczyk T, Undas A. The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome. *Thromb Res.* 2017;152:93-97.
- 117. Haładyj E, Olesińska M. Rivaroxaban: a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases. *Reumatologia*. 2016;54(3):146-149.
- 118. Resseguier AS, Pereira B, Rieu V, Le Guenno G, Grobost V, Ruivard M. Direct oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome? *Lupus*. 2017;26(12):1297-1303.
- 119. Son M, Wypasek E, Celinska-Lowenhoff M, Undas A. The use of rivaroxaban in patients with antiphospholipid syndrome: A series of 12 cases. *Thromb Res.* 2015;135(5):1035-1036.
- Gundabolu K, Bhatt VR, Lunning MA, Baljevic M. Efficacy of direct oral anticoagulants (DOAC) in patients with antiphospholipid antibody syndrome (APS) [abstract]. *Blood.* 2017;130(suppl 1). Abstract 4917.
- Leblebjian H, Parnes A. Direct oral anticoagulants in anti-phospholipid syndrome [abstract]. *Blood.* 2017;130(suppl 1). Abstract 2145.